Investors & Media
Our science-driven strategy allows us to advance our programs with sound execution and ultimately bring long-term value to patients. Follow the journey of our dedicated scientists and drug developers or learn how you can contribute to our mission.
Our science-driven strategy allows us to advance our programs with sound execution and ultimately bring long-term value to patients. Follow the journey of our dedicated scientists and drug developers or learn how you can contribute to our mission.
Investor Opportunities
Contact UsLatest News
임시주주총회 기준일 공고
April 23, 2025
퍼스트바이오, HPK1 저해제 경쟁력 확인…AACR 발표·임상 1상 순항 중
April 23, 2025
퍼스트바이오, 파킨슨병 신약 연구 글로벌 컨소시엄 참여
April 15, 2025
1STBIO Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research
April 15, 2025
퍼스트바이오-리가켐바이오, 공동연구 및 기술이전 옵션 계약 체결
April 8, 2025
제9기 정기주주총회 소집공고
March 17, 2025
퍼스트바이오, 세계적 암 연구기관 ‘모핏’과 면역항암제 개발 협력
February 11, 2025
Moffitt Cancer Center and 1ST Biotherapeutics Announce Strategic Alliance To Transform Cancer Treatment
February 11, 2025
리가켐바이오와 ADC 공동연구로 새로운 항암 치료 가능성 탐색
December 13, 2024
